These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27260863)

  • 1. Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.
    Aldridge J; Décary-Hétu D
    Int J Drug Policy; 2016 Sep; 35():7-15. PubMed ID: 27260863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing cryptomarkets for drugs. A characterisation of sellers and buyers over time.
    Tzanetakis M
    Int J Drug Policy; 2018 Jun; 56():176-186. PubMed ID: 29449105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery dilemmas: How drug cryptomarket users identify and seek to reduce their risk of detection by law enforcement.
    Aldridge J; Askew R
    Int J Drug Policy; 2017 Mar; 41():101-109. PubMed ID: 28089207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Going international? Risk taking by cryptomarket drug vendors.
    Décary-Hétu D; Paquet-Clouston M; Aldridge J
    Int J Drug Policy; 2016 Sep; 35():69-76. PubMed ID: 27453145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safer scoring? Cryptomarkets, social supply and drug market violence.
    Barratt MJ; Ferris JA; Winstock AR
    Int J Drug Policy; 2016 Sep; 35():24-31. PubMed ID: 27241015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transparency paradox. Building trust, resolving disputes and optimising logistics on conventional and online drugs markets.
    Tzanetakis M; Kamphausen G; Werse B; von Laufenberg R
    Int J Drug Policy; 2016 Sep; 35():58-68. PubMed ID: 26809972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forensic drug intelligence and the rise of cryptomarkets. Part II: Combination of data from the physical and virtual markets.
    Morelato M; Broséus J; De Grazia A; Tahtouh M; Esseiva P; Roux C
    Forensic Sci Int; 2018 Jul; 288():201-210. PubMed ID: 29763810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who sells what? Country specific differences in substance availability on the Agora cryptomarket.
    Van Buskirk J; Naicker S; Roxburgh A; Bruno R; Burns L
    Int J Drug Policy; 2016 Sep; 35():16-23. PubMed ID: 27520115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'What if you live on top of a bakery and you like cakes?'-Drug use and harm trajectories before, during and after the emergence of Silk Road.
    Barratt MJ; Lenton S; Maddox A; Allen M
    Int J Drug Policy; 2016 Sep; 35():50-7. PubMed ID: 27157539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Offline constraints in online drug marketplaces: An exploratory analysis of a cryptomarket trade network.
    Norbutas L
    Int J Drug Policy; 2018 Jun; 56():92-100. PubMed ID: 29621742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing market competition and vendors' size and scope on AlphaBay.
    Paquet-Clouston M; Décary-Hétu D; Morselli C
    Int J Drug Policy; 2018 Apr; 54():87-98. PubMed ID: 29414490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterising dark net marketplace purchasers in a sample of regular psychostimulant users.
    Van Buskirk J; Roxburgh A; Bruno R; Naicker S; Lenton S; Sutherland R; Whittaker E; Sindicich N; Matthews A; Butler K; Burns L
    Int J Drug Policy; 2016 Sep; 35():32-7. PubMed ID: 26872846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains.
    Gilbert M; Dasgupta N
    Int J Drug Policy; 2017 Aug; 46():160-167. PubMed ID: 28735772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Nice people doing shady things': Drugs and the morality of exchange in the darknet cryptomarkets.
    Masson K; Bancroft A
    Int J Drug Policy; 2018 Aug; 58():78-84. PubMed ID: 29870962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmedical prescription psychiatric drug use and the darknet: A cryptomarket analysis.
    Cunliffe J; Décary-Hêtu D; Pollak TA
    Int J Drug Policy; 2019 Nov; 73():263-272. PubMed ID: 30772109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An island apart? Risks and prices in the Australian cryptomarket drug trade.
    Cunliffe J; Martin J; Décary-Hétu D; Aldridge J
    Int J Drug Policy; 2017 Dec; 50():64-73. PubMed ID: 29055855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixing politics and crime - The prevalence and decline of political discourse on the cryptomarket.
    Munksgaard R; Demant J
    Int J Drug Policy; 2016 Sep; 35():77-83. PubMed ID: 27424175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we smoke it for you as well? An ethnographic analysis of a drug cryptomarket environment.
    Kowalski M; Hooker C; Barratt MJ
    Int J Drug Policy; 2019 Nov; 73():245-254. PubMed ID: 31054880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forensic drug intelligence and the rise of cryptomarkets. Part I: Studying the Australian virtual market.
    Broséus J; Morelato M; Tahtouh M; Roux C
    Forensic Sci Int; 2017 Oct; 279():288-301. PubMed ID: 28927690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.